AMYLYX PHARMACEUTICALS INC's ticker is and the CUSIP is 03237H101.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,466,183 | -15.1% | 899,300 | 0.0% | 0.19% | -16.1% |
| Q2 2023 | $19,397,901 | +52.3% | 899,300 | +107.1% | 0.23% | +32.9% |
| Q1 2023 | $12,739,428 | -32.2% | 434,200 | -14.6% | 0.17% | -31.1% |
| Q4 2022 | $18,783,643 | -34.6% | 508,353 | -50.2% | 0.25% | -37.4% |
| Q3 2022 | $28,724,000 | +282.2% | 1,020,384 | +161.5% | 0.40% | +245.7% |
| Q2 2022 | $7,516,000 | +49.9% | 390,229 | 0.0% | 0.12% | +43.2% |
| Q1 2022 | $5,014,000 | – | 390,229 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 2,756,050 | $35,415,000 | 3.44% |
| Boxer Capital, LLC | 2,200,000 | $28,270,000 | 1.45% |
| Alpha Wave Global, LP | 617,220 | $7,931,000 | 0.72% |
| Ikarian Capital, LLC | 396,654 | $5,097,000 | 0.67% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 768,603 | $9,877,000 | 0.58% |
| Ikarian Capital, LLC | 250,000 | $3,213,000 | 0.42% |
| 683 Capital Management, LLC | 677,714 | $7,685,000 | 0.41% |
| Perceptive Advisors | 1,474,107 | $18,942,000 | 0.38% |
| VIKING GLOBAL INVESTORS LP | 7,170,536 | $92,141,000 | 0.37% |
| Rock Springs Capital Management LP | 998,307 | $12,828,000 | 0.32% |